Edward Scolnick,Jeffrey R. Cottrell,Florence Fevrier Wagner,Edward Holson,Michael C. Lewis,Mark Firman Bear,Laura Stoppel,Arnold Heynen
申请号：
US15260262
公开号：
US20160375006A1
申请日:
2016.09.08
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present disclosure provides methods of using GSK3α-selective inhibitors for treating Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder. The GSK3α-selective inhibitors include compounds of Formula I-A. The present disclosure also provides methods of using GSK3β-selective inhibitors for treating a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder. The GSK3β-selective inhibitors include compounds of Formula I-B.
